Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Forsberg

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|November 25, 2023
SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic MalignanciesMark Forsberg, Marina Konopleva
Trends in Pharmacological Sciences|April 20, 2024
AML treatment: conventional chemotherapy and emerging novel agentsMark Forsberg, Marina Konopleva
Case Reports in Oncology|November 11, 2020
Infectious Mononucleosis Causing Acute Liver Failure and Hemolytic Anemia in a Patient with Underlying Hereditary HemochromatosisMark Forsberg, Mark Galan, Joshua Kra
Neuropharmacology|December 24, 2014
Tasimelteon: a selective and unique receptor binding profileChristian Lavedan, Mark Forsberg, Anthony J Gentile
Cureus|June 3, 2021
Pulmonary Large Cell Neuroendocrine Carcinoma: A Rare Type of Non-Small Cell Lung CancerThomas G Ng, Hyo-Bin Um, Mark Forsberg, et al.
Frontiers in Oncology|March 11, 2026
TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approachesShweta Deshpande, Wing Fai Li, Junmin Song, et al.
Frontiers in Oncology|March 30, 2026
Correction: TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approachesShweta Deshpande, Wing Fai Li, Junmin Song, et al.
Open Forum Infectious Diseases|February 19, 2021
Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 PatientsMarc Klapholz, Sri Ram Pentakota, Juan-Pablo Zertuche, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
British Journal of Haematology|August 28, 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodiesOthman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Lymphoma, Myeloma & Leukemia|November 25, 2023
SOHO State of the Art Updates and Next Questions: Understanding and Overcoming Venetoclax Resistance in Hematologic MalignanciesMark Forsberg, Marina Konopleva
Trends in Pharmacological Sciences|April 20, 2024
AML treatment: conventional chemotherapy and emerging novel agentsMark Forsberg, Marina Konopleva
Case Reports in Oncology|November 11, 2020
Infectious Mononucleosis Causing Acute Liver Failure and Hemolytic Anemia in a Patient with Underlying Hereditary HemochromatosisMark Forsberg, Mark Galan, Joshua Kra
Neuropharmacology|December 24, 2014
Tasimelteon: a selective and unique receptor binding profileChristian Lavedan, Mark Forsberg, Anthony J Gentile
Cureus|June 3, 2021
Pulmonary Large Cell Neuroendocrine Carcinoma: A Rare Type of Non-Small Cell Lung CancerThomas G Ng, Hyo-Bin Um, Mark Forsberg, et al.
Frontiers in Oncology|March 11, 2026
TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a 3 comprehensive overview of targeted approachesShweta Deshpande, Wing Fai Li, Junmin Song, et al.
Frontiers in Oncology|March 30, 2026
Correction: TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a comprehensive overview of targeted approachesShweta Deshpande, Wing Fai Li, Junmin Song, et al.
Open Forum Infectious Diseases|February 19, 2021
Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 PatientsMarc Klapholz, Sri Ram Pentakota, Juan-Pablo Zertuche, et al.
Blood Cancer Journal|March 5, 2024
Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyMeera Mohan, Jorge Monge, Nishi Shah, et al.
British Journal of Haematology|August 28, 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodiesOthman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi, et al.
Pageof 1